Nicolas PY – Director, Head of Market Intelligence - General Secretary of Strategic Committees – Debiopharm International SA | LinkedIn
![Kaiku Health Raises €4.4 Million Series A Financing to Accelerate Its Digital Therapeutics Pipeline Led by Debiopharm and Tesi Kaiku Health Raises €4.4 Million Series A Financing to Accelerate Its Digital Therapeutics Pipeline Led by Debiopharm and Tesi](https://mma.prnewswire.com/media/663163/Debiopharm_Logo.jpg?p=facebook)
Kaiku Health Raises €4.4 Million Series A Financing to Accelerate Its Digital Therapeutics Pipeline Led by Debiopharm and Tesi
Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset From ImmunoGen - ADVFN
![Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen | Business Wire Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen | Business Wire](https://mms.businesswire.com/media/20170523006128/en/588548/4/ImmunoGen_logo.jpg)
Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen | Business Wire
Laila Barki email address & phone number | Debiopharm International Sa Executive Search Talent Acquisition Partner contact information - RocketReach
Tom Gibbs email address & phone number | Debiopharm International Sa Director, Debiopharm Innovation Fund contact information - RocketReach
![Debiopharm International SA and Solid Biosciences, LLC, announce a collaboration to explore the use of Alisporivir (Debio 025) in muscular dystrophy. | Col6.it - Collagen VI Italy - English Version Debiopharm International SA and Solid Biosciences, LLC, announce a collaboration to explore the use of Alisporivir (Debio 025) in muscular dystrophy. | Col6.it - Collagen VI Italy - English Version](http://www.col6.it/en/wp-content/uploads/sites/3/2015/11/2000px-Ciclosporin.svg_.png)